| Company Name: |
Alfa Chemistry |
| Tel: |
1-516-6625404 |
| Email: |
support@alfa-chemistry.com |
|
| | C18 3'-sulfo Galactosylceramide (d18:1/18:0) Basic information |
| Product Name: | C18 3'-sulfo Galactosylceramide (d18:1/18:0) | | Synonyms: | C18 3'-sulfo Galactosylceramide (d18:1/18:0);-sulfo Galactosylceramide (d18:1/18:0);Octadecanamide, N-[(1S,2R,3E)-2-hydroxy-1-[[(3-O-sulfo-β-D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]-;N-Octadecanoyl-sulfatide;N-[(1S,2R,3E)-2-hydroxy-1-[[(3-O-sulfo-β-D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]-octadecanamide | | CAS: | 244215-65-4 | | MF: | C42H81NO11S | | MW: | 808.16 | | EINECS: | | | Product Categories: | | | Mol File: | 244215-65-4.mol |  |
| | C18 3'-sulfo Galactosylceramide (d18:1/18:0) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Chloroform:Methanol (5:1): soluble | | form | A solid |
| | C18 3'-sulfo Galactosylceramide (d18:1/18:0) Usage And Synthesis |
| Description | C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.1 C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.2,3 Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.4 It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).5 Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.2,6 As this product is derived from a natural source, there may be variations in the sphingoid backbone. | | Uses | N-Octadecanoyl-sulfatide is an ester product. | | Definition | ChEBI: 3-O-Sulfogalactosylceramide (d18:1/18:0) is a glycosphingolipid. | | References | 1. Takahashi, T., and Suzuki, T. Role of sulfatide in normal and pathological cells and tissues J. Lipid Res. 53(8),1437-1450(2012).
2. Isaac, G., Pernber, Z., Gieselmann, V., et al. Sulfatide with short fatty acid dominates in astrocytes and neurons FEBS J. 273(8),1782-1790(2006).
3. Moyano, A.L., Li, G., Lopez-Rosas, A., et al. Distribution of C16:0, C18:0, C24:1, and C24:0 sulfatides in central nervous system lipid rafts by quantitative ultra-high-pressure liquid chromatography tandem mass spectrometry Anal. Biochem. 467,31-39(2014).
4. Moyano, A.L., Pituch, K., Li, G., et al. Levels of plasma sulfatides C18 : 0 and C24 : 1 correlate with disease status in relapsing-remitting multiple sclerosis J. Neurochem. 127(5),600-604(2013).
5. Saville, J.T., Smith, N.J.C., Fletcher, J.M., et al. Quantification of plasma sulfatides by mass spectrometry: Utility for metachromatic leukodystrophy Anal. Chim. Acta 955,79-85(2017).
6. Svennerholm, L., and Stllberg-Stenhagen, S. Changes in the fatty acid composition of cerebrosides and sulfatides of human nervous tissue with age J. Lipid Res. 9(2),215-225(1968). |
| | C18 3'-sulfo Galactosylceramide (d18:1/18:0) Preparation Products And Raw materials |
|